OCTN2 Activates a Non‐Canonical Carnitine Metabolic Pathway to Promote MASH‐HCC Progression and Immunotherapy Resistance
Advanced Science · 2026
DOI: 10.1002/advs.202517054 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Chuqi Xia und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Surgery, The Second Affiliated Hospital of Kunming Medical University, Kunming, China. Hauptthemen laut MEDLINE: Liver Neoplasms, Carnitine, Solute Carrier Family 22 Member 5, Carcinoma, Hepatocellular. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Yunnan Fundamental Research Kunming Medical University Joint Projects, Yunnan Revitalization Talent Support Program.
Abstract (Originalsprache)
Metabolic dysfunction‐associated steatohepatitis related hepatocellular carcinoma (MASH‐HCC) is a distinct HCC subtype characterized by lipid accumulation, impaired fatty acid oxidation (FAO), immune evasion, and resistance to immunotherapy. In this study, we observed elevated levels of L‐carnitine—a classical FAO activator—and its transporter OCTN2 in MASH‐HCC. Mechanistically, L‐carnitine is redirected from FAO promotion to buffering intracellular acetyl groups via conversion to acetyl‐L‐carnitine, leading to acetyl group depletion. This disrupts protein acetylation through two distinct pathways: reduced acetylation of p53 weakens its tumor‐suppressive signaling and promotes tumor progression, while decreased acetylation of histone H3 impairs MHC‐I antigen presentation, facilitating immune evasion. We further identified that the lncRNA LINCMD1 competitively bound the E3 ligase DZIP3, sequestering it in the nucleus and preventing its interaction with cytoplasmic OCTN2. This inhibited K48‐linked ubiquitination of OCTN2 and stabilized its protein expression, further amplifying L‐carnitine accumulation. To therapeutically target this axis, we developed a liver‐specific lipid nanoparticle (LNP)‐delivered antisense oligonucleotide against the DZIP3‐binding region of LINCMD1, which restored p53 and MHC‐I pathways and enhanced anti–PD‐1 efficacy in vivo. Together, our findings uncover a noncanonical carnitine‐driven metabolic–epigenetic–immune bypass in MASH‐HCC and identify the LINCMD1/DZIP3/OCTN2–L‐carnitine axis as a potential therapeutic target.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastrointestinal Surgery, The Second Affiliated Hospital of Kunming Medical University, Kunming, China.
- TUM School of Medicine and Health, Technical University of Munich, Munich, Germany.
- Division of Liver Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, China.
- Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Kunming Medical University, Kunming, China.
- Department of Gastrointestinal Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
- Zhongnan Hospital, Wuhan University, Wuhan, China.
ORCID-Profile: Xu Li
Förderung
- National Natural Science Foundation of China
- Yunnan Fundamental Research Kunming Medical University Joint Projects
- Yunnan Revitalization Talent Support Program
Zitieren
APA
Xia, C., Zhang, X., Li, J., Xu, N., Hu, S., Lu, Q., Li, Y., Xiao, T., Li, X., Wang, X., Xu, K., & Liang, D. (2026). OCTN2 Activates a Non‐Canonical Carnitine Metabolic Pathway to Promote MASH‐HCC Progression and Immunotherapy Resistance. Advanced Science. https://doi.org/10.1002/advs.202517054
Vancouver
Xia C, Zhang X, Li J, Xu N, Hu S, Lu Q, et al. OCTN2 Activates a Non‐Canonical Carnitine Metabolic Pathway to Promote MASH‐HCC Progression and Immunotherapy Resistance. Advanced Science. 2026. doi:10.1002/advs.202517054
BibTeX
@article{Xia2026,
author = {Xia, Chuqi and Zhang, Xiao and Li, Jinze and Xu, Ning and Hu, Sheng and Lu, Qiyu and Li, Yuxuan and Xiao, Taifu and Li, Xu and Wang, Xue and Xu, Kequan and Liang, Daoming},
title = {OCTN2 Activates a Non‐Canonical Carnitine Metabolic Pathway to Promote MASH‐HCC Progression and Immunotherapy Resistance},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.202517054}
}
EUVIMED